Breast MRI

Radswiki et al.

Breast MRI is the most sensitive method for detection of breast cancer. Depending on international health regulations, it is either applied for screening of women at high risk for developing breast cancer (e.g. BRCA-1 and BRCA-2 carriers), as an additional diagnostic test in pretherapeutic breast cancer staging, monitoring of primary systemic therapies and for solving problematic diagnostic situations were direct biopsy is not possible. 

Editorial board note: this article is probably outdated, lacks structure and is in need of a major rewrite. If you are interested in refining it you are more than welcome.

  • dynamic T1-weighted gradient echo before and after IV Gd injection
  • T2w-TSE or STIR sequences
  • diffusion Weighted Imaging (DWI)
  • further techniques such as e.g. proton MR-spectroscopy seldom applied outside research settings
  • amount of fibroglandular tissue (FGT)
    • almost entirely fat: ACR a
    • scattered fibroglandular tissue: ACR b
    • heterogeneous fibroglandular tissue: ACR c
    • extreme amount of fibroglandular tissue: ACR d
  • background Parenchymal Enhancement (BPE)
    • minimal
    • mild
    • moderate
    • marked

Usually, enhancing lesions are meant. Absence of enhancement practically excludes breast cancer with an NPV>99%.

  • focus (formerly defined as < 5 mm): enhancement too small to be characterised, should be considered as BPE if symmetric and multiple
  • mass enhancement (space occupying lesion, best diagnostic clue: margins can be assessed)
    • shape: round (unspecific), oval (rather benign), irregular (rather suspicious)
    • margins: circumscribed (benign), Non-circumscribed (rather suspicious), spiculated (highly suspicious)
    • internal enhancement pattern: homogenous (rather benign), heterogenous (unspecific), rim (rather suspicious, in particular, if centripetal, filling up over time), dark internal septations (rather benign), old BI-RADS included central enhancement (part of the lesion enhances, highly specific for fibroadenoma)
  • non-mass enhancement (best diagnostic clue: margins cannot be assessed due to diffuse enhancement or grouped multiple spots; Non-mass are far more difficult to distinguish and reflect different pathological entities)
    • distribution pattern: focal, linear (rather suspicious), regional, multiple regional, segmental (rather suspicious)
    • Internal enhancement pattern: homogeneous (rather benign), heterogeneous (unspecific), clumped (rather suspicious), clustered ring (rather suspicious, seldomly seen), old BI-RADS included stippled, a homogeneous grainy enhancement typically benign
    •  
  • in all lesions: enhancement kinetics: see breast MRI enhancement curves
    • Washout (rather suspicious), Plateau (unspecific), Persistent (rather benign) (caveat: Lymph nodes show Washout but typical morphology)
  • BIRADS 0: incomplete/non-diagnostic - this category should not be used for marked BPE, motion artifacts etc
  • BIRADS I: negative (no enhancing lesions, no benign changes such as scars, cysts etc)
  • BIRADS II: benign (lymph nodes, inflamed cysts, fibroadenoma, fat necrosis, foci/stippled enhancement, patchy BPE).
  • BIRADS III: probably benign, requiring short term follow-up in 6 months. If the finding is visible on e.g. US, the most widely available method should be used for follow-up (should be applied only to lesions not fitting category II and IV, probably benign findings in high-risk screening should rather be biopsied than followed-up)
  • BIRADS IV: suspicious finding requiring biopsy (Biopsy should always be tried by US first as the majority of MRI lesions can be localized by targeted ultrasound
  • BIRADS V: highly suspicious, biopsy mandatory
  • BIRADS VI: known, histologically verified cancer

Diagnosis is established by combining morphological and functional criteria. A circumscribed round lesion with persistent enhancement is a typical fibroadenoma while the same lesion presenting with Washout may be cancer (typical in high risk population, aggressive cancers).

Clinical history and correlation with mammography is not only diagnostically useful (e.g. to reduce the number of BIRADS III category assignments) but should be considered in the report as well in order to demonstrate the referring physician that the clinical question has been answered.

  • in high risk screening population : 3 - 4% prevalence when mammography was negative ( 0.3 % when mammo and ultrasound negative)
  • 7% if personal history of cancer
  • positive predictive value 24% ( ½ invasive 4 mm median size/ ½ DCIS)
    • biopsy recommended in 17%
  • contralateral breast
    • 5% prevalence
    • 20 % positive predictive value (biopsy recommended in 1/3) (NEJM 3/29/07: Bx rec in 12 % PPV 25 %);
  • Ipsilateral breast
    • ~ 25%
    • 50% PPV (biopsy recommended in 50%)

Ipsilateral multifocal ¾ (same quadrant > 1cm from index CA or contiguous but extends > 4 cm) multicentric ¼; distribution similar to recurrent disease

Additional sites of ipsilateral cancer more frequent if +FH (42%) & ILC (55%)

Positive predictive value higher the closer the lesion is to the index cancer.

Biopsy to get histological diagnosis no matter how suspicious because result is Mx

Younger patients because of 1 - 2% / year recurrence may also benefit from preop MRI

True and false positive rate decreases with each subsequent comparison MRI

  • IDC / ILC : > 90%
  • DCIS : 80 - 90%
  • implant rupture : ~ 94 % 9
  • high risk screening
  • extent of disease (EOD) evaluation in ipsilateral and contralateral breast
  • positive margins (better accuracy further from lumpectomy site than near Lx site b/c postop enh/changes)
  • neo-adjuvant chemotherapy : to assess residual disease
  • metastatic axillary lymphadenopathy of unknown primary (75 - 80% sensitive) - can spare a patient from having management because may be able to undergo BCT; management path only finds cancer in two-thirds
  • posterior lesion to assess chest wall invasion (pectoralis can be resected so not considered
  • chest wall stage IIIB - serratus anterior, rib, intercostal muscles)
  • BRCA+ : BRCA 1 or BRCA 2
  • 1st degree relative BRCA+ and untested
  • those who have had prior radiotherapy to chest wall 
  • > 25% lifetime risk based on genetic models (some of which take breast density into consideration)
  • not recommended if lifetime risk < 15 % because of high false positive rate
  • problem solving (e.g. post operative breasts with distortion)
  • recurrent breast cancer / scar changes (not usual before 2 - 3 years; peak 5 - 7 years; increased risk if EIC, younger age, positive margins (wait at least 1 month post op to scan), no RT)
  • to assess for synchronousmultifocal or multicentric disease
  • spiculated mass : 80 %
  • irregular shape : 32 %
  • < 5 mm mass : 3 %
  • calcifications
    • segmental : 67 %
    • clumped ductal : 31 %
  • malignant causes : DCIS, invasive cancer
  • benign high risk causes : ADH, LCIS
  • benign : fibrosis, ductal hyperplasia, fibrocystic change
  • 40-50 % cancers should be < 1 cm
  • at least 20-30% should be DCIS
  • positive nodes < 20%
  • technical causes : breast tissue not included in the coil, motion, bad contrast injection, too much compression
  • marked background enhancement

Caveat : if mammography or ultrasound is positive or palpable finding need to treat / biopsy / excise despite negative MRI !

MSKCC : only 23% probably low but if lesion is less than 1 cm or deep within lots of background parenchyma in a large breast may want to go directly to MR guided biopsy.

Breast imaging and pathology
Share article

Article information

rID: 12182
Systems: Breast, Oncology
Section: Approach
Synonyms or Alternate Spellings:
  • MRI breast
  • MRI of the breast
  • Magnetic resonance imaging of the breast
  • MR-mammography

Support Radiopaedia and see fewer ads

Cases and figures

  • Drag
    VIBRANT +C early ...
    Case 1 : showing breast cancer + lipoma
    Drag here to reorder.
  • Drag
    3D VIBRANT +C
    Case 2 : showing invasive ductal carcinoma
    Drag here to reorder.
  • Drag
    Case 3 : showing invasive lobular carcinoma
    Drag here to reorder.
  • Drag
    Fig. 1

Sagittal T2
    Case 4 : showing extra-capsular implant rupture
    Drag here to reorder.
  • Drag
    Subtraction image
    Case 5 : showing multicentric lobular cancer
    Drag here to reorder.
  • Drag
    CAD colour flow m...
    Case 5 : colour coded image shows large breast cancer
    Drag here to reorder.
  • Drag
    On post contrast ...
    Case 6: pseudoangiomatous stromal hyperplasia
    Drag here to reorder.
  • Drag
    This is a type I ...
    Case 7: enhancement curve
    Drag here to reorder.
  • Drag
    Case 8: high grade ductal carcinoma in situ
    Drag here to reorder.
  • Updating… Please wait.
    Loadinganimation

    Alert accept

    Error Unable to process the form. Check for errors and try again.

    Alert accept Thank you for updating your details.